FGF2 and lung carcinoma: We studied pre-treatment and pre-cycle four plasma levels of VEGF, sVEGFR-2, IL-8, TNF-α, sICAM-1 and bFGF in an unselected cohort of patients from these trials to analyse the biological effects of thalidomide treatment, and to investigate their utility as biomarkers in lung cancer.